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ABSTRACT
All-trans retinoic acid (ATRA) is a potent inducer of
cell differentiation and growth arrest. Here, we
investigated ATRA-induced regulatory cascades
associated with growth arrest of the human hepa-
toma cell line HepG2. ATRA induced `2-fold
changes in the expression of 402 genes including
55 linked to cell-cycle regulation, cell growth or
apoptosis during 48h treatment. Computational
search predicted that 250 transcriptional regulatory
factors (TRFs) could recognize the proximal
upstream regions of any of the 55 genes. Expression
of 61 TRF genes was significantly changed during
ATRA incubation, providing many potential regula-
tory edges. We focused on six TRFs that could
regulate many of the 55 genes and found a total of
160 potential edges in which the expression of each
of the genes was changed later than the expression
change of the corresponding regulator. RNAi knock-
down of the selected TRFs caused perturbation of
the respective potential targets. The genes showed
an opposite regulation pattern by ATRA and specific
siRNA treatments were selected as strong candi-
dates for direct TRF targets. Finally, 36 transcrip-
tional regulatory edges were validated by chromatin
immunoprecipitation. These analyses enabled us
to depict a part of the transcriptional regulatory
cascades closely linked to ATRA-induced cell
growth arrest.
INTRODUCTION
All-trans retinoic acid (ATRA), a derivative of retinol
(vitamin A), can regulate important biological processes
such as cell diﬀerentiation and proliferation (1,2). ATRA
binds to retinoic acid receptors (RARs), which are
heterodimerized with the retinoid receptors (RXRs) and
induces a protein conformational change to recruit
coactivators leading to the transcriptional activation of
their target genes (3,4). In the absence of the ligand, RAR/
RXR heterodimer binds to its speciﬁc DNA sequences,
retinoic acid response elements (RAREs) composed typi-
cally of two direct repeats of a core motif, PuG(G/T)TCA,
and represses their target genes through recruitment of the
corepressors NCoR and SMRT (5,6). When ATRA binds
to RAR, RAR/RXR can activate transcription of their
target genes (3,4). Because each of the RAR genes has a
recognition site for their own protein products in their
regulatory region, once it is activated by ATRA, its
expression is auto-activated (7) except for the RARG1
gene, one of the isoforms of RARG, which can repress the
activation of RARE (8,9). Many genes have been reported
as retinoic acid responsive genes (10). However, how the
transcriptional cascades and networks relevant to ATRA-
induced biological events function remains unclear.
Dynamic transcriptional regulation is a key event that
leads to time-, tissue- and/or cell-speciﬁc eukaryotic gene
expression in response to extracellular signals. Identiﬁca-
tion of the transcriptional regulatory edges consisting of
transcriptional regulatory factors (TRFs) and their regu-
lated genes is important for understanding the mecha-
nisms of a given biological phenomenon. We have been
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edges by using overexpression or RNAi knockdown of
the TRF genes triggering perturbation of their regulated
genes and cross-linking-chromatin immunoprecipitation
(X-ChIP) to conﬁrm the interactions between TRFs and
their target DNA elements (11,12). In the present study,
we applied this experimental scheme in combination with
time-course expression proﬁling to analyze the dynamic
transcriptional regulatory cascades related to ATRA-
induced biological events as a model system.
In human hepatoma-derived HepG2 cells, ATRA
inhibits G1/S transition in the cell cycle and results in
growth arrest (13). We investigated the transcriptional
regulatory cascades involved in the growth arrest of
HepG2 cells induced by ATRA. First, the time-dependent
ATRA-induced perturbation of gene expression was
examined to extract the potential ATRA-responsive
genes, which were then ﬁltered according to gene ontology
for cell-cycle regulation, cell growth or apoptosis. Second,
TRFs that could regulate the ﬁltered ATRA-responsive
genes were selected by examining the location of their
potential binding sites in the proximal upstream regions
of their potential targets and their time-course expression
proﬁles. Third, highly reliable edges were detected by
RNAi knockdown of the selected six TRF genes and by
quantifying the perturbation levels of their potential
targets. Finally, X-ChIP analysis validated a number of
direct and nondirect regulatory edges, leading to depiction
of the transcriptional regulatory cascades linked to growth
arrest of HepG2 cells.
MATERIALS AND METHODS
Reagents
ATRA and DMSO were purchased from Sigma (St Louis,
MO, USA).
Cellculture andATRA treatment
HepG2 cells were obtained from RIKEN Bioresource
Center (Tsukuba, Japan) and cultured in Minimum
Essential Medium Eagle (Sigma) with 1mM sodium
pyruvate (Sigma) supplemented with 10% fetal bovine
serum at 378C in a 5% CO2 and 95% atmosphere. HepG2
cells were seeded in 15cm dishes and cultured for 24h so
that they would be 50% conﬂuent at the time of ATRA
treatment. Cells were washed with PBS twice, and then
exposed to fresh medium with 50mM ATRA dissolved in
DMSO or with only DMSO. These cells were incubated
at 378Ci naC O 2 incubator for 72h. Total RNAs were
prepared at 6, 12, 24, 36 and 48h and used for expression
analysis. To investigate the cell growth rates, we counted
viable cells by trypan blue exclusion assays at each time
point.
siRNA transfection and RNA extraction
The synthetic siRNAs targeting human CEBPA, DDIT3,
EGR1, RARA, RARB and SREBF1 were purchased
from Invitrogen (Supplementary Table 1). Transfection
of HepG2 cells with siRNAs (at a ﬁnal concentration
of 20nM) in Opti-MEM medium (Invitrogen, Carlsbad,
CA, USA) by using siPORT NeoFX (Ambion,
Woodward, TX, USA) was done 24h before ATRA
treatment according to the manufacturer’s protocol. We
used Negative Control #1 siRNA (Ambion) as the control.
Total RNA was extracted 48h after siRNA administration
from cells treated with ATRA or only DMSO with the
NucleoSpin RNA II total RNA isolation kit (Macherey-
Nagel, Germany) containing RNase-free DNaseI accord-
ing to the manufacturer’s instructions. The yield and
purity of RNA were spectrophotometrically determined.
Microarray analysis
First-strand cDNA was synthesized from 500ng of total
RNA, then second-strand DNA was synthesized with
DNA polymerase and used to degrade the RNA with
RNase H simultaneously. After puriﬁcation of the cDNA,
this became a template for in vitro transcription with T7
RNA polymerase. In this step, multiple copies of
biotinylated cRNA were produced. The puriﬁed cRNA
was ready for hybridization. All steps were done with the
Illumina RNA Ampliﬁcation Kit (Ambion) according to
the manufacturer’s instructions. The concentration of the
cRNA solution was determined by spectrophotometric
measurement, and the size distribution of cRNA was
evaluated using an Agilent 2100 Bioanalyzer. Next, cRNA
was hybridized using Sentrix Human-6 Expression
BeadChips (Illumina, San Diego, CA, USA) for gene
expression proﬁling according to the manufacturer’s
instructions. Hybridization was done four times for each
cRNA sample, and the signal intensity of each data set
was cut oﬀ at <0.01 P-values. The data were analyzed
with BeadStudio (Illumina), and genes with the expression
ratio of ATRA-treated samples compared with DMSO-
treated samples that showed >2-fold increase (>2.0) or
decrease (<0.5) in signal intensity ratio were considered to
be ATRA-modulated genes and the remaining genes were
excluded for further examination. We registered all
Illumina microarray data to CIBEX (DDBJ, accession
number CBX36).
Search forpotential transcription factor-bindingsites
The upstream regions (2.2kb) extending from 2000 to
+200 relative to the transcription start sites of the ATRA-
modulated genes were extracted from the UCSC database.
We searched the proximal promoter region of transcrip-
tion factor-binding sites using the MATCH program (14)
of the Transfac database (Biobase) and the TESS program
(http://www.cbil.upenn.edu/tess/techreports/1997/CBIL-
TR-1997-1001-v0.0.pdf and http://www.cbil.upenn.edu/
tess?RQ=WELCOME for WEB searching). The cut-oﬀ
to minimize false positive matches (minFP) was applied
when searching the DNA sequences.
Quantitative real-time RT–PCR (qRT–PCR)
Total RNA was reverse-transcribed using Ex-script
(Takara Bio, Shiga, Japan) with random 6mer primers.
The resultant cDNAs were used as templates for PCR
reaction with SYBR Premix Ex Taq Perfect Real Time
(Takara Bio), 2.5ml of 1:5 diluted cDNA and gene-speciﬁc
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The primer sets used for real-time RT–PCR analysis are
shown in Supplementary Tables 2 and 3 (for expression
analysis of TRF genes and validation of the TRF-
regulated gene pairs, respectively). PCR reaction was
carried out on the ABI PRISM 7500 Fast Real-Time PCR
System (Applied Biosystems) by denaturation at 958C for
10s, followed by running for 40 cycles at 958C for 5s and
62.58C for 20s. The expression ratio was calculated
according to the 2
C
T method (12,15).
X-ChIP/quantitative real-time PCR (qPCR)
The procedures for X-ChIP were essentially as described
elsewhere (11) with some modiﬁcations. The soluble
chromatin was incubated with anti-CEBPA, DDIT3,
EGR1, RARA, RARB, SREBF1 speciﬁc antibodies (sc-
61, sc-7351, sc-189, sc-551, sc-552 and sc-17755, respec-
tively; SantaCruz Biotechnology, Santa Cruz, CA, USA)
for >12h at 48C. The chromatin–antibody mixture was
incubated with Dynabeads Protein G (Dynal Biotech,
Oslo, Norway) for 1h at 48C and the immunoprecipitates
were captured using magnets. The recovered immunopre-
cipitates were washed once with IP wash buﬀer Low
(2mM EDTA, 20mM Tris–HCl pH 8.0, 150mM NaCl,
1% Triton X-100, 0.1% SDS), once with IP wash buﬀer
High (2mM EDTA, 20mM Tris–HCl pH 8.0, 500mM
NaCl, 1% Triton X-100, 0.1% SDS), once with IP wash
buﬀer LiCl (1mM EDTA, 10mM Tris–HCl pH 8.0,
250mM LiCl, 0.5% NP-40, 0.5% sodium deoxycholate)
and twice with TE buﬀer (10mM Tris–HCl pH 8.0, 1mM
EDTA). The reversal of formaldehyde-induced cross links
was carried out by heating at 658C for 3.5h with 200mM
NaCl and RNaseI (Nippon Gene, Tokyo, Japan) treated
at 658C for 0.5h. The reversal cross-linked complexes were
treated with 0.05mg/ml proteinase K (Nippon Gene) at
458C for 1h. Released DNA was extracted with phenol
and phenol:chloroform:isoamyl alcohol (25:24:1), then
ethanol-precipitated and dissolved in 100mlo fH 2O. DNA
obtained by ChIP with TRF-speciﬁc antibody, from
the precipitates without any antibody and input DNA
(total chromatin DNA) were used as templates for qRT–
PCR. The PCR mixture contained 2ml of DNA prepara-
tion, 200nM of each of the speciﬁc primer sets, and SYBR
Premix ExTaq (Takara) in a total volume of 10ml. The
speciﬁc primer sets were designed so as to amplify the
DNA fragments surrounding the potential binding
sequence of TRF detected as described in the analysis of
consensus TRF binding sequences. These primer
sequences are presented in Supplementary Table 4. The
PCR reaction was carried out under the same conditions
as those for expression analysis.
RESULTS
ATRA-induced growth arrest ofHepG2 cells
First, the concentration of ATRA to induce arrest of the
growth of HepG2 cells was determined. HepG2 cells were
cultured in the presence or absence of various concentra-
tions of ATRA ranging from 10 to 50mM, and the cell
count was determined by trypan blue exclusion assay.
HepG2 cells treated with 50mM of ATRA reproducibly
showed clear growth inhibition within 48h after the start
of treatment (Figure 1). On the other hand, lower
concentrations of ATRA did not exhibit complete
growth arrest of HepG2 cells under the conditions used.
Time-course analysis ofATRA-induced geneexpression
changes
To search for the genes aﬀected by ATRA treatment, we
comprehensively analyzed expression proﬁles at 6, 12, 24,
36 and 48h after the start of incubation with the retinoid
with Sentrix Human-6 Expression BeadChips covering
about 47 300 diﬀerent human transcripts. The time-course
expression proﬁling data were grouped into three: two
biological replicates, each of which consisted of two
technical replicates, and the set of all the four replicates
(two biological and two technical replicates). The data
in each of these three groups were normalized indepen-
dently. Only genes whose expression levels were signiﬁ-
cantly changed in two or all of the three groups were
selected for further analysis. We identiﬁed 402 genes that
were upregulated or downregulated in ATRA-treated cells
>2-fold as compared with the levels of genes in DMSO-
treated cells at any of the time points examined
(Supplementary Table 5). In HepG2 cells, the growth
arrest induced by ATRA was not accompanied by any
change in the cyclin D1 expression level, whereas a
reduction was observed in a previous study (16). Instead,
expression of cyclin D2 was increased at an early stage
of ATRA treatment and the mRNA level remained high
up to 48h.
RARA and RARB genes were upregulated by ATRA,
but the expression signal of the latter was not detected
with the RNA sample prepared from the DMSO-treated
cells. On the other hand, no detectable level of hybridiza-
tion signals for RARG gene expression was obtained,
indicating that its expression was very low even after
ATRA induction in HepG2 cells. We then tried to analyze
their expression levels by qRT–PCR and found that the
mRNA level of RARB was greatly increased within 6h
after ATRA administration, but the RARG gene expres-
sion remained at very low levels throughout the 48-h cell
culture with ATRA.
Figure 1. Cell number of HepG2 cells treated with 50mM ATRA or
0.1% DMSO. ATRA induced growth arrest of HepG2 within 48h.
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within 6h. Because these immediate early genes may be
the promising candidates for the direct targets of RARs,
we examined whether they had a RARE in their upstream
regions from 2000 to +200bp relative to their tran-
scriptional start sites. To search for potential RAR-
binding sites with the MATCH program of TRANSFAC
(Table 1), we used two kinds of matrix proﬁles
(V$DR1_Q3 and V$DR4_Q2 with the accession numbers
M00762 and M00965, respectively) deﬁned on the basis of
the sequence data including RAR–RXR heterodimer-
binding sites. The genomic DNA sequences of two genes
(MATND6 and Hs.508390) on the Sentrix Human-6
Expression BeadChips were not found in public DNA
databases. This search detected 27 genes (60% of the 45
genes) that had a potential RAR recognition site in their
proximal upstream regions (Table 1).
To probe the cascades involved in the ATRA-induced
cell growth arrest of HepG2, we selected 55 from 402
genes based upon their known relatedness to the processes
of cell cycle, cell growth and/or apoptosis according to
Gene Ontology (Table 2).
Search oftranscription factor genesinvolved inATRA
response
Next, we searched for the potential TRF-binding sites in
the proximal upstream regions of the 55 selected ATRA-
induced genes by using the MATCH program in
TRANSFAC and detected them for a total of 250
diﬀerent TRFs in the upstream regions of these genes.
We then analyzed the time-dependent changes in the
expression levels of these TRF genes. Among them, the
expression levels of 109 TRF genes were high enough to be
Table 1. Immediate early ATRA-inducible genes having a RARE in their proximal upstream regions
Gene Refseq ID Position Matrix Sequence
ADAMTS4 NM_005099 403(+) V$DR1_Q3 gggcCAAAGggca
BHLHB2 NM_003670 1934(+) V$DR1_Q3 agcgCAGAGgtca
DDIT3 NM_004083 735(+) V$DR4_Q2 tgacctcaagTGATCcg
DNAJB9 NM_012328 487(+) V$DR1_Q3 agccCAAAGgcca
480(+) V$DR1_Q3 aggcCACAGgtcc
FSTL3 NM_005860 731(+) V$DR1_Q3 aggaCAAAGgcca
+63() V$DR1_Q3 tggcCTCTGccct
HMGCS1 NM_002130 +154() V$DR1_Q3 tggaCTTTGcccg
HOZFP NM_152995 1706(+) V$DR4_Q2 tgacctaaggTGATCca
296() V$DR4_Q2 caGGTGAgtttagggca
IGFBP6
 NM_002178 667(+) GGTCaNNNNNNGTTCA
KCNJ10 NM_002241 1709(+) V$DR4_Q2 tgcccgtgaaTGACCtc
KNG NM_000893 1798() V$DR4_Q2 caGATCActagaggtca
LCAT NM_000229 1827(+) V$DR4_Q2 tgccctgcccTGGCCcc
LOC389058 NM_001003845 1694(+) V$DR1_Q3 gggaGATAGgtca
LOC144100 NM_175058 527(+) V$DR4_Q2 tggactcgatTAACCtt
217(+) V$DR1_Q3 gggaCAAAGgccg
LOC55971 NM_018842 1580(+) V$DR4_Q2 tgacctcaagTGATCcg
1488() V$DR1_Q3 agacCTCTGccct
NR0B2 NM_021969 787(+) V$DR4_Q2 tgacctcaaaTGATCcc
OSTalpha NM_152672 1757(+) V$DR1_Q3 cggcCACAGctca
OSTbeta NM_178859 1191() V$DR4_Q2 tgGATCAcctgaggtca
PGRP-L NM_052890 134() V$DR1_Q3 tgacCACTGacct
RBP1 NM_002899 547(+) V$DR4_Q2 tgacctcaggTGATCcg
SDS-RS1 NM_138432 1235() V$DR1_Q3 tgatCTCTGccca
1119() V$DR1_Q3 agacCTTTGcact
901(+) V$DR1_Q3 aggcCAAAGttcc
380(+) V$DR4_Q2 agacctaagcTGACCcc
+158(+) V$DR1_Q3 tgggCAAAGtcca
SGK NM_005627 1940() V$DR4_Q2 gaGCTCActttagggca
1775() V$DR4_Q2 gaGGTCAtggcagggca
SLC16A5 NM_004695 1214(+) V$DR1_Q3 gaggCAAAGgtca
826() V$DR4_Q2 tgGATCAcctgaggtca
SLC22A3 NM_021977 569(+) V$DR4_Q2 tgccctgcccTGCCCca
176() V$DR1_Q3 cgacCTGTGgccc
SOS1 NM_005633 1797(+) V$DR4_Q2 tgacctcaggTGATCca
TCEA2 NM_003195 700(+) V$DR4_Q2 tgacctcaggTGATCca
TGM2
 NM_198951 969(+) AGGTcANNNNNGGGTGA
1528(+) GGtCANNNNNNGGTCA
+152(+) GGtCANNNNNGGTCA
UPP1 NM_003364 888(+) V$DR4_Q2 tgacctcaggTGATCca
Forty-seven genes induced within 6h after the start of ATRA treatment were detected by microarray analysis using Sentrix Human-6 Expression
BeadChips. A search for the potential RAR binding sequences in their proximal upstream regions from 2000 to +200bp relative to their
transcriptional start sites was carried out with the MATCH program of TRANSFAC and the TESS program. Twenty-seven genes were found to
have one or more RAREs. Two genomic sequences corresponding to the transcripts (MTND6 and Hs.508390) included in the Sentrix Human-6
Expression BeadChips were not found in public databases. The potential RAR-binding sites of the two genes with an asterisk were searched for using
the TESS program because no RARE was detected in their proximal upstream regions by using TRANSFAC matrices.
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BeadChips could not be used to evaluate the expression
levels of 141 genes because their expressions were too
weak to be detected eﬀectively by this technique. Their
levels were examined using qRT–PCR, and 62 genes were
found to be poorly expressed in HepG2 cells either before
or after ATRA treatment. Therefore, the remaining 79
genes were examined for the time-dependent changes in
their expressions with qRT–PCR. We found that ATRA
treatment changed the expression levels of 61 out of the
188 TRF genes (109 and 79 genes based on microarray
and qRT–PCR data, respectively) >1.5-fold as compared
with the control (only incubation with DMSO) at any of
the time points tested (Table 3). If a TRF regulates
expression of some other genes, the time points when the
expression levels of the regulated genes are changed are
expected to be later than when the TRF gene expression
is changed. Based on this assumption, we selected a total
of 886 pairs of TRFs and their regulated genes from all
combinations of 55 genes perturbed >2-fold by ATRA
treatment and classiﬁed by GO as the genes related to the
cell growth regulatory processes with 61 TRFs whose
expression levels were changed >1.5-fold (based on the
data of qRT–PCR analysis) before the 2-fold changes
in the expression of the corresponding candidate
regulated genes.
Validation ofthe regulatory relationships by expression
perturbation upon knockdownof specific TRFs
To conﬁrm the TRF-regulated gene pairs, we analyzed
expression perturbation of the candidate-regulated genes
by knockdown of the corresponding TRF genes. From
a list of 61 TRFs, we chose six TRFs, RARA, RARB,
CEBPA, DDIT3, EGR1 and SREBF1 having candidate
regulated genes of 18, 18, 39, 26, 16 and 43, respectively
(160 genes in total). All of these six TRFs are upregulated
by ATRA treatment. Both RARA and RARB were
chosen because the ATRA-induced regulatory cascades
should originate from them. It was found that CEBPA
and SREBF1 had many regulated gene candidates, 39 and
43 genes, respectively, and therefore were considered to
play important roles in ATRA-induced regulatory cas-
cades. DDIT3 (also known as CHOP-10) is a CEBP
family member and known to be induced by stress leading
to cell growth arrest and/or apoptosis (17). It has been
reported that EGR1 induces cell growth arrest and
regulation of EGR1 is involved in the MAPK pathway
(18), a master regulatory process of the G1 to S-phase
transition (19).
Knockdown of the six TRF genes was performed twice
by addition of 20nM (ﬁnal concentration) of speciﬁc
siRNAs 24h before the start of ATRA treatment.
Expression of all these six TRF genes was repressed
throughout the 48h ATRA treatment (Figure 2). We
analyzed the expression levels of all of their regulated gene
candidates at 6, 12, 24, 36 and 48h after ATRA addition
with qRT–PCR and selected 47 genes (9, 8, 13, 5, 2 and 10
genes for RARA, RARB, CEBPA, DDIT3, EGR1 and
SREBF1, respectively) whose expression levels were
changed >1.5-fold by siRNA targeting the respective
Table 2. ATRA-induced expression changes of genes linked to cell
growth, apoptosis and/or cell cycle
Symbol RefSeq ID 6h 12h 24h 36h 48h
ANXA3
 NM_005139 2.56 2.83 2.24
AREG NM_001657 3.88
BHD NM_144606 2.50
BMP4 NM_130851 0.44
C20orf97 NM_021158 2.51 3.12 3.84
CARD9 NM_052814 2.63 2.48
CCND2 NM_001759 2.09
CNK NM_004073 3.52
CTGF NM_001901 0.46
DDIT3 NM_004083 2.22 2.01 2.38 4.09 3.98
DTNA NM_001392 2.26
DUSP1 NM_004417 2.69 2.65
DUSP6 NM_022652 0.42 0.37 0.38
ELF5 NM_001422 0.40
FABP3 NM_004102 0.42
FGA NM_021871 2.37 2.44
FGB NM_005141 2.55 3.44 2.36
FGG NM_000509 2.44 2.06 2.08
FLJ30999 NM_152461 2.94
FLJ31051 NM_153687 0.43
FSCN1 NM_003088 0.39
FSTL3 NM_005860 4.99 3.80 4.30 7.88 9.95
GPC6 NM_005708 2.26 2.14 2.82
HYPE NM_007076 2.91 2.30
IFITM1 NM_003641 0.41 0.29
IGF2 NM_000612 2.39 2.09 4.50 5.11 9.80
IGFBP1 NM_000596 2.27
IGFBP6 NM_002178 2.15
IGFBP7 NM_001553 0.48 0.33
IL17RB NM_018725 0.43
INHBE NM_031479 2.94 6.65 5.63 4.71
LIF NM_002309 4.69
LOC117584 NM_057178 0.47
MAPK13 NM_002754 2.36
MDK NM_002391 2.37
MGC8685 NM_178012 3.24 3.78 4.38
MLLT3 NM_004529 0.45
MLLT7 NM_005938 0.49
MXD4 NM_006454 0.36
NEDD9 NM_182966 0.40
OKL38 NM_182981 2.40 2.23
PDZK1 NM_002614 0.47 0.45 0.31 0.23
PEG10 NM_015068 0.36 0.29
PLAB NM_004864 2.72 2.45
PLAU NM_002658 0.43 0.38 0.34
PPP1R15A NM_014330 3.66 3.87
RARA NM_000964 2.21 2.65
SESN2 NM_031459 2.29 2.39 2.85
SGK NM_005627 0.33 0.23 0.18 0.26
TGM2
 NM_198951 2.24 2.25
TNFRSF12A NM_016639 2.70
TNFRSF19 NM_018647 0.34
TNFSF10 NM_003810 0.42 0.46
TUBE1 NM_016262 2.66 2.88
WARS NM_004184 2.40
The expression ratio represents the ratio of the expression level in the
cells treated with ATRA to that in those incubated with only DMSO
for the periods of time indicated. The four proﬁling data sets (two
biological and two technical replicates) were categorized into three
groups: each of the biological replicates and a sum of all the four
replicates. Only data exhibited a P-value <0.01 were extracted and only
genes whose expression levels were signiﬁcantly changed in two or all of
the three groups were selected. Results are the average of two or three
groups of data analyzed. Genes with an asterisk were not assigned
to any GO category, but are known to be related to cell growth or
apoptosis (34,35).
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Symbol RefSeq ID 6h 12h 24h 36h 48h Detection
BHLHB2 NM_003670 2.06 2.02 2.21 2.28 2.46 Illumina
CEBPA NM_004364 1.49 1.49 1.69 1.89 2.04 Illumina
CEBPD NM_005195 0.89 0.74 0.72 0.63 0.56 Illumina
CEBPG NM_001806 1.12 1.29 1.49 1.56 1.81 Illumina
CUTL1 NM_181500 1.36 1.07 1.01 2.20 2.09 Illumina
DDIT3 NM_004083 2.22 2.01 2.38 4.09 3.98 Illumina
DEAF1 NM_021008 0.75 (0.06) 0.67 (0.13) 0.75 (0.13) 0.85 (0.20) 0.91 (0.29) qPCR
EGR1 NM_001964 0.94 0.69 0.94 3.15 5.15 Illumina
ELF4 NM_001421 1.36 1.90 1.16 0.92 1.46 Illumina
ETV6 NM_001987 1.00 1.03 1.12 1.56 1.20 Illumina
FOS NM_005252 0.51 (0.22) 0.27 (0.06) 0.55 (0.18) 0.46 (0.08) 0.76 (0.21) qPCR
FOSL2 NM_005253 0.80 0.64 0.98 0.88 1.10 Illumina
FOXF1 NM_001451 0.91 (0.03) 1 (0.05) 0.88 (0.13) 1.11 (0.14) 2.19 (0.41) qPCR
FOXF2 NM_001452 1.14 (0.06) 1.12 (0.03) 1 (0.31) 2.19 (0.62) 4.32 (1.13) qPCR
FOXJ2 NM_018416 0.68 (0.05) 0.79 (0.11) 1.11 (0.12) 1.56 (0.01) 4.63 (0.33) qPCR
GABPB2 NM_016655 1.21 1.14 1.09 1.36 1.79 Illumina
GFI1 NM_005263 0.83 0.84 0.89 0.57 0.93 Illumina
GFI1B NM_004188 0.42 (0.08) 0.39 (0.08) 0.35 (0.06) 0.4 (0.05) 0.34 (0.02) qPCR
GLI1 NM_005269 1.86 (0.46) 1.5 (0.43) 0.72 (0.26) 0.91 (0.06) 1.02 (0.50) qPCR
HIF1A NM_181054 0.97 (0.21) 0.82 (0.12) 0.6 (0.11) 1.03 (0.17) 0.77 (0.2) qPCR
HNF4A NM_178850 0.62 (0.08) 0.9 (0.1) 0.95 (0.15) 0.99 (0.06) 1.02 (0.17) qPCR
HNF4G NM_004133 0.67 (0.1) 0.72 (0.14) 0.94 (0.21) 1.24 (0.24) 1.23 (0.32) qPCR
HOXA5 NM_019102 4.50 3.59 3.70 4.34 4.27 Illumina
IRF1 NM_002198 1.01 0.86 1.19 1.35 1.73 Illumina
JUN NM_002228 0.87 (0.23) 0.82 (0.25) 0.79 (0.20) 1.41 (0.35) 1.68 (0.37) qPCR
JUNB NM_002229 0.75 (0.13) 0.63 (0.05) 0.86 (0.23) 1.09 (0.13) 1.53 (0.35) qPCR
MAD NM_002357 1.5 (0.09) 1.17 (0.13) 1.25 (0.21) 1.79 (0.08) 1.87 (0.43) qPCR
MAFF NM_152878 1.1 (0.08) 1.03 (0.49) 1.11 (0.25) 1.49 (0.16) 2.6 (0.46) qPCR
MAFK NM_002360 1.31 (0.09) 1.21 (0.18) 1.06 (0.14) 1.22 (0.20) 2.2 (0.49) qPCR
NFATC2 NM_012340 0.36 (0.07) 0.54 (0.03) 0.81 (0.05) 1.02 (0.09) 1.12 (0.21) qPCR
NR1H3 NM_005693 0.98 (0.38) 0.93 (0.18) 1.07 (0.11) 0.94 (0.38) 1.98 (0.44) qPCR
NR1H4 NM_005123 0.90 1.20 1.49 1.58 1.47 Illumina
NR1I2 NM_022002 0.85 0.58 0.63 0.60 0.58 Illumina
NR2F1 NM_005654 0.86 0.53 0.67 0.71 0.63 Illumina
NRF1 NM_005011 0.63 (0.06) 0.84 (0.17) 1.4 (0.33) 1.28 (0.33) 1.51 (0.34) qPCR
PAX6 NM_000280 2.14 (0.23) 1.58 (0.28) 1.5 (0.05) 1.47 (0.23) 2.97 (0.40) qPCR
PAX8 NM_013992 1.04 0.77 1.08 0.76 0.67 Illumina
PBX3 NM_006195 0.55 1.08 1.06 0.90 1.13 Illumina
PGR NM_000926 1 (0.23) 0.93 (0.26) 0.98 (0.28) 1.03 (0.27) 1.99 (0.25) qPCR
POU6F1 XM_352901 1.6 (0.34) 1.53 (0.24) 1.12 (0.21) 1.11 (0.05) 0.67 (0.15) qPCR
RARA NM_000964 1.48 1.56 1.52 2.21 2.65 Illumina
RARB NM_016152 7.37 (2.74) 7.11 (2.12) 9.64 (3.05) 10.62 (3.62) 12.44 (3.96) qPCR
RARG NM_000966 0.57 (0.24) 0.78 (0.16) 0.56 (0.19) 0.74 (0.09) 0.75 (0.07) qPCR
RFX5 NM_000449 0.84 0.84 0.94 0.74 0.58 Illumina
RFXANK NM_134440 0.82 0.64 1.05 1.39 1.10 Illumina
RXRA NM_002957 0.66 0.73 0.88 0.81 0.67 Illumina
SP2 NM_003110 0.98 0.95 0.63 0.90 0.77 Illumina
SREBF1 NM_004176 2.26 2.31 2.31 2.21 2.20 Illumina
SREBF2 NM_004599 0.66 0.77 1.35 1.44 1.14 Illumina
SRY NM_003140 0.5 (0.08) 0.69 (0.04) 0.82 (0.05) 0.59 (0.05) 0.51 (0.04) qPCR
STAT2 NM_005419 0.99 1.08 0.97 0.72 0.64 Illumina
STAT6 NM_003153 1.19 0.91 1.04 0.65 0.81 Illumina
TCF2 NM_000458 0.80 1.07 0.86 0.86 0.68 Illumina
TCF7 NM_003202 1.40 1.17 1.33 1.45 1.95 Illumina
TP53 NM_000546 1.20 1.27 0.69 0.94 1.59 Illumina
USF2 NM_003367 1.34 1.09 1.25 1.50 1.51 Illumina
VDR NM_000376 1.53 (0.16) 1.45 (0.13) 0.92 (0.08) 0.84 (0.03) 0.77 (0.16) qPCR
ZBTB33 NM_006777 0.7 (0.01) 0.56 (0.01) 0.69 (0.00) 0.66 (0.04) 0.56 (0.09) qPCR
ZIC2 NM_007129 1.15 1.14 1.23 1.24 1.93 Illumina
ZNF219 NM_016423 0.84 0.73 0.65 0.91 0.77 Illumina
ZNF238 NM_006352 0.68 (0.38) 0.72 (0.18) 0.74 (0.13) 1.08 (0.08) 0.63 (0.15) qPCR
Expression levels of the genes not detected by microarray were analyzed using qRT–PCR. The expression ratio represents the ratio of expression
levels in the cells treated with ATRA to that in those incubated with only DMSO for the periods of time indicated. Results are the average of two or
three groups of data analyzed with Illumina microarrays and the average of four data sets (a combination of two sets of biological replicates)
obtained by qRT–PCR analysis with SD values in parenthesis.
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basis that all of these six TRF genes were upregulated by
ATRA treatment (Table 3), we considered that genes
regulated by each of these six TRFs would be reversely
regulated by ATRA treatment and RNAi knockdown of
the TRF gene. Knockdown of each of the six TRF genes
led to detection of a total of 36 out of 160 genes (7/18,
6/18, 11/39, 3/26, 1/16, 8/43 for RARA, RARB, CEBPA,
DDIT3, EGR1 and SREBF1, respectively) that clearly
exhibited such a reverse regulatory pattern by ATRA
treatment and knockdown of the respective TRF (Figure 3
for several examples; Supplementary Table 6). These genes
and the corresponding TRFs are strong candidates for
direct transcriptional regulatory edges in the regulatory
cascades related to ATRA-induced growth arrest. In
addition, 11 other genes were signiﬁcantly perturbed by
a speciﬁc siRNA in either of the two experiments and
showed the reverse regulatory pattern. Therefore, these
genes were also selected as potential candidates for direct
regulatory node.
Confirmation of thededuced edgesby X-ChIP/qPCR
Next, we conﬁrmed whether these candidate edges
would be really direct or indirect ones by examining the
physical binding of the TRFs to their regulated genes with
X-ChIP/qPCR technique. The cross-linked DNA samples
were extracted from HepG2 cells at ﬁve time points after
ATRA or DMSO treatment, and these samples were
immunoprecipitated with antibodies speciﬁc for each of
the six TRFs. DNA fragments were liberated from the
proteins, puriﬁed and used as templates for qPCR
ampliﬁcation. Primer sets that were speciﬁc to the DNA
regions of the candidate regulated genes containing a
potential recognition sequence for the TRFs were used.
We determined the Ct-values of the speciﬁc DNA regions
by using DNA samples recovered with or without the
speciﬁc antibody to calculate the diﬀerence Ct as an
indicator of the speciﬁc DNA fragment enrichment.
Ct-values >1.0 were evaluated as a positive binding of
each TRF to its cognate DNA regions. Bindings of a
total of 36 genes by any of the ﬁve TRFs were
demonstrated (Table 4) and these genes could qualify as
highly reliable direct regulatory edges. No signiﬁcant
chromatin binding was observed in X-ChIP/qPCR for
SREBF1. This is due to the low speciﬁcity and/or aﬃnity
of the SREBF1 antibody used because it has failed to
recover the positive control DNA region derived from the
PPARG gene (data not shown).
Figure 2. Expression levels of the six selected TRF genes suppressed by respective siRNAs at several time points. HepG2 cells were transfected with
each of the speciﬁc siRNAs (20nM, ﬁnal concentration) 24h before ATRA addition, and the total RNA was extracted 6, 12, 24, 36 and 48h after
ATRA addition. The expression ratio was calculated according to the 2
C
T method as described in ‘Materials and methods’ section with GAPDH
mRNA and negative control siRNA as the internal reference and the calibrator, respectively. The data are the averages of two biological replicates.
Nucleic Acids Research, 2008, Vol. 36, No. 10 3449Figure 3. Reverse perturbation patterns of gene expression induced by RNAi knockdown and ATRA treatment. Expression perturbations of the
selected TRF-regulated genes by knockdown of the corresponding TRF genes are on the left. The expression ratio was calculated as in the legend to
Figure 2. The reversed regulatory pattern was observed by ATRA treatment (right). The expression ratio was normalized by the expression level
observed with DMSO treatment and the data are the averages as described in the caption of Table 3. Black and white bars indicate upregulation and
downregulation, respectively. Data for the time points when the clear reverse regulatory patterns were conﬁrmed are shown.
3450 Nucleic Acids Research, 2008, Vol. 36, No. 10Integration of all the data obtained from time-course
expression analysis with ATRA treatment, searching for
the potential TRF recognition sequences, perturbation
upon RNAi knockdown of TRFs and X-ChIP/qPCR
enables us to depict the transcriptional regulatory
cascades as shown in Figure 4. To estimate statistical
signiﬁcance, we measured P-values with four replicates for
each gene described in ‘Time-course analysis of ATRA-
induced gene expression changes’ by a t-test. This analysis
extracted 5593 and 2540 genes at all time points (6, 12, 24,
36 and 48h) with the ﬁlters of P<0.05 and 0.01,
respectively. Selection based on GO classiﬁcation left
425 and 192 genes with the ﬁlters of P<0.05 and 0.01,
respectively. Finally, 39 and 29 genes in 55 genes, which
were extracted by our original analysis with the criterion
of >2-fold perturbation and GO selection, were found in
the 425 and 192 genes, respectively. We found 23 (85%)
out of the 27 genes ﬁnally selected to depict the
transcriptional cascades (Figure 4; RARB was excluded
because its expression level was not assessed by micro-
array but by qRT–PCR, EGR1 and SREBF1 were
excluded because GO did not suggest any relatedness of
these TRFs to cell growth regulation) in the 39 genes with
a P-value <0.05. This implies that four out of the 27 genes
(15%) are left out of the most probable regulated genes
that appear in the cascades. If we would apply P<0.01 to
a threshold, 10 genes (37%) would be omitted.
The thresholds of P=0.05 and 0.01 correspond to the
false discovery rates (FDR) or q-values of 0.058–0.153 and
0.030–0.086, which have been estimated by using
QVALUE software (20). Q-values were calculated based
on P-values estimated with the data sets (four replicates of
ATRA/DMSO- and DMSO-treated HepG2 cells) at the
time points of 6, 12, 24, 36 and 48h after the start of
ATRA/DMSO and DMSO treatment. There are 163
uncharacterized genes (192 – 29 genes) with a P-value
<0.01. Although we have not yet searched for potential
recognition sites for six selected TRFs in the neighboring
DNA region of each of the 163 genes, they might contain
a few genes to be regulated by these TRFs.
Knockdownof CEBPA gene induced growth
arrestinhibition
If transcriptional regulation by a TRF is critical for the
control of cell growth arrest, perturbation of its expression
may lead to some phenotypic change. Therefore, we
checked the growth of the cells treated with siRNA
speciﬁc to each of the TRFs as the typical phenotypic
change and found that the ATRA-induced growth arrest
of HepG2 cells was suppressed when the CEBPA gene was
repressed by a speciﬁc siRNA (Figure 5). In sharp
contrast, knockdown of any other of the ﬁve TRF genes
did not cause any detectable phenotypic changes. In the
present study, we identiﬁed several CEBPA-regulated
genes (Figure 4). Among them, we noted that ATRA
markedly induced downregulation of PLAU, urokinase
plasminogen activator gene, between 12 and 36h after
ATRA addition. In addition, PLAU was upregulated
(>13-fold on average) by CEBPA knockdown (Figure 3).
Moreover, we found that PLAU had multiple binding
sites for CEBPA in its proximal upstream region and
demonstrated the CEBPA binding to the PLAU DNA
region in vivo. These results indicate that ATRA-induced
upregulation of CEBPA repressed PLAU expression
during the growth arrest of HepG2 cells.
DISCUSSION
The present study revealed a part of the ATRA-induced
transcriptional cascades related to the growth arrest of
HepG2 cells. For investigation of the cascades, we used
a combination of time-course comprehensive expression
proﬁling, searching for TRF recognizable sequences, time-
course expression proﬁling of TRF genes and chromatin-
binding assay. To probe the TRF-regulated genes, we
noted the diﬀerence in the times for the changes in the
mRNA levels of TRFs and their regulated genes. After a
TRF gene is transcribed, the mRNA should be processed,
exported from the nucleus, translated on cytoplasmic
ribosomes and the resultant proteins return into the
nucleus to promote transcription of its target genes.
Table 4. X-ChIP/qPCR analysis of the ﬁve TRFs and their regulated
gene candidates
TF Time Regulated
gene
Ct TF Time Regulated
gene
Ct
CEBPA 36h DDIT3 3.58 RARA 24h DDIT3 1.47
CEBPA 12h DUSP6 2.61 RARA 36h DDIT3 1.13
CEBPA 36h DUSP6 2.48 RARA 48h DDIT3 1.23
CEBPA 36h FGA 2.98 RARA 06h FSTL3 5.59
CEBPA 36h FGB 2.07 RARA 12h FSTL3 3.42
CEBPA 48h IFITM1 1.77 RARA 36h FSTL3 5.07
CEBPA 36h INHBE 3.71 RARA 48h FSTL3 4.75
CEBPA 48h MLLT3 2.78 RARA 48h MAPK13 2.37
CEBPA 36h MLLT7 2.07 RARA 48h MDK 5.11
CEBPA 12h PDZK1 2.45 RARA 48h NEDD9 4.23
CEBPA 48h PEG10 3.27 RARA 12h PDZK1 3.06
CEBPA 48h PLAB 2.33 RARA 24h PDZK1 3.14
CEBPA 12h PLAU 1.79 RARA 36h PDZK1 3.38
CEBPA 24h PLAU 1.29 RARA 48h PDZK1 2.67
CEBPA 36h SESN2 3.03 RARA 48h PEG10 3.91
CEBPA 36h TUBE1 1.28 RARA 06h RARA 1.88
RARA 12h RARA 2.46
DDIT3 06h DDIT3 1.70 RARA 24h RARA 3.45
DDIT3 36h DDIT3 1.81 RARA 36h RARA 3.08
DDIT3 48h DDIT3 3.00 RARA 48h RARA 2.91
DDIT3 24h DUSP6 1.26 RARA 06h RARB 2.32
RARA 12h RARB 3.00
RARB 48h FABP3 1.84 RARA 24h RARB 4.54
RARB 48h MAPK13 2.41 RARA 36h RARB 4.23
RARB 36h PDZK1 2.63 RARA 48h RARB 3.84
RARB 48h PDZK1 2.36 RARA 48h SESN2 2.67
RARB 36h PEG10 1.91
RARB 48h PEG10 1.14 EGR1 48h LIF 3.68
RARB 06h RARB 1.74 EGR1 48h PEG10 6.56
RARB 12h RARB 3.19 EGR1 48h TGM2 3.50
RARB 24h RARB 2.21 EGR1 48h TNFRSF12A 5.75
RARB 36h RARB 2.62
RARB 48h RARB 3.20
RARB 48h SREBF1 2.63
The extent of enrichment of DNA regions was calculated by using the
following equation: Ct=Ct (sample recovered with antibody)Ct
(sample recovered without antibody). The data are the averages from
two independent experiments.
Nucleic Acids Research, 2008, Vol. 36, No. 10 3451Therefore, there should be a time lag between the induction
of the TRF gene and their regulated genes. For example,
expression of EGR1 was markedly changed 36h after
ATRA treatment and the known EGR1-regulated gene
TP53 changed its expression level by >1.5-fold at 48h
(Table 3). This supports the idea that the TRF-regulated
genes can be selected by noting the time lag between the
abrupt change in the expression of the TRF gene in
question and its regulated gene candidates.
The present study provides new insights into the
mechanisms of cell growth arrest by ATRA. ATRA
exhibits crosstalks with various signaling pathways such
as PI3K/Akt (21), p38 MAPK pathway (22) and TGFb/
Smad pathway (23). Cellular retinol-binding protein 1
(RBP1) inhibits in an ATRA-dependent manner the
assembly of p85 and p110 subunits that form activated
PI3 kinase (PI3K) leading to the activation of Akt (protein
kinase B) (24). We found that RBP1 gene was induced
immediately after ATRA addition (Supplementary
Table 5) as RARA and RARB were and had a RARE
in its proximal upstream region (Table 1), suggesting that
it may be directly regulated by these RARs.
The complex of PLAU and its receptor interacts with
integrin leading to signal transduction via the MAPK
pathway that stimulates cell growth (25). It has been
reported that ATRA treatment increased the levels of
expression of PLAU and its receptor in human epidermal
keratinocyte (26). In sharp contrast, we found that PLAU
expression was repressed by ATRA treatment in HepG2
cells. We also demonstrated that PLAU was negatively
regulated by CEBPA in HepG2 cells, where CEBPA gene
expression is stimulated by ATRA leading to eﬀective
suppression of PLAU. On the other hand, the EGR1 gene
is functionally implicated in cell proliferation and
diﬀerentiation processes (27,28) and plasminogen/plasmin
regulates EGR1 expression via the MEK/ERK pathway
(29). Consistent with this, we found EGR1 induction at
mid-late stage of ATRA-induced HepG2 cell growth
arrest after the signiﬁcant decrease of PLAU expression
had started at an early stage. These results strongly
suggest a multitiered regulatory network comprised of
CEBPA, PLAU, plasminogen/plasmin, EGR1, integrin
and MAPK pathway.
The p38 MAP kinase pathway is activated in an ATRA-
dependent manner in acute promyelocytic leukemia and
breast carcinoma cell lines (22). However, its direct
regulator has not yet been identiﬁed. We found that
p38d (MAPK13) expression was signiﬁcantly increased in
HepG2 cells by ATRA treatment (Table 2). Moreover,
our RNAi knockdown and X-ChIP/qPCR results oﬀer
evidence of the direct regulation of p38d MAPK by
Figure 4. Transcriptional cascades involving six ATRA-stimulated TRFs. Bold lines indicate the edges validated by both RNAi knockdown of TRFs
and X-ChIP/qPCR. The edges shown as thin lines were revealed by TRF binding but the perturbation was not highly reproducible. The edges
indicated by broken lines were not detected by X-ChIP/qPCR but by perturbation experiments. The broken lines from SREBF1 were drawn on the
basis of RNAi knockdown data. Perturbation of EGR1 expression was less reproducible. The dotted lines emitting from or directed to GFI1 and
GFI1B were speculated from our experiments and the literature information (see Discussion section for details). These cascades were drawn by
Cytoscape 2.4.1(http://www.cytoscape.org/).
Figure 5. Knockdown of CEBPA inhibits ATRA-induced growth arrest
of HepG2 cells. CEBPA-speciﬁc siRNA was administrated 24h before
the addition of ATRA and cell number was counted at the time points
indicated in triplicate and the ratio to that at 12h after ATRA
treatment. HepG2 cells transfected with negative control siRNA (NC)
showed growth arrest by ATRA, but CEBPA-suppressed cells did not.
3452 Nucleic Acids Research, 2008, Vol. 36, No. 10RARA and RARB. Interestingly, ATRA also markedly
stimulates INHBE encoding activin bE and this gene was
identiﬁed to be regulated by CEBPA. Speciﬁc inhibitors of
the p38 kinase completely abolish the activin-mediated cell
growth inhibition of human breast cancer T47D cells (30).
Therefore, we propose a cascade of ATRA stimulation of
RARA, RARB and CEBPA genes, stimulation of p38 by
RARs and activin-mediated activation of the MAPK
leading to cell growth arrest.
CEBPA has been known as a target gene of GFI1 in
promyelocytic KG-1 cells, monocytic cells and Jurkat
T cells (31). The transcriptional activity of GFI1 was
regulated by GFI1B (32). GFI1B and GFI1 are zinc ﬁnger
transcriptional repressors, which in turn repress their own
expression (32,33). Because GFI1B has a RARE in its
regulatory region and its expression level was repressed for
48h after ATRA treatment (Table 3), it may be directly
regulated by RARs. In our analysis, the GFI1 gene
expression was repressed at 36h and then CEBPA gene
expression was signiﬁcantly upregulated. These ﬁndings
with literature information suggest a possible ATRA-
GFI1B-GFI1-CEBPA transcriptional regulatory cascade.
We conﬁrmed the growth arrest of HeLa cells by ATRA
treatment as observed with HepG2 cells and found that
several genes showed quite similar time-lapse expression
patterns as found in HepG2 cells but several genes did not
(our unpublished data). This ﬁnding suggests that some of
the gene regulatory events occurred in HepG2 cells may be
common (or partially common) to another cell types with
diﬀerent genetic background. The marked diﬀerences in
the expressions of some genes between HepG2 and HeLa
cells may be indicators of some diﬀerent mechanism of cell
growth arrest in these two cell types. Extensive investiga-
tion with HeLa cells by the same approach as applied to
HepG2 cells could aﬀord insights into the regulatory
mechanisms relevant to cell growth arrest.
Our experimental approach focusing on the six TRFs
successfully revealed the transcriptional regulatory cas-
cades related to the growth arrest of HepG2 cells.
Although these cascades are only a portion of the entire
process, this approach could be applied to further
elucidate the transcriptional regulatory events involved
in the cell growth arrest. The present study also showed
that RNAi knockdown of TRFs is a powerful tool for
investigating dynamically changing transcriptional regu-
latory networks.
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Supplementary Data are available at NAR Online.
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